Oncology News
Stay updated on oncology with press releases highlighting research, treatments, and innovations advancing cancer care and management. Learn about key developments shaping oncology and explore opportunities in cancer research and patient support.
Mar 13, 2026 at 4:05 PM
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Mar 13, 2026 at 8:15 AM
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be cap...
Mar 13, 2026 at 8:05 AM
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first...
Mar 13, 2026 at 8:00 AM
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies reports financial results for FY 2025, including record revenue and unit sales for the CyPath Lung test for lung cancer....
Mar 13, 2026 at 7:30 AM
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform. In addition, a Phase I program (QUILT-3.076; NCT04898543) combining M-ceNK with ANKTIVA® (nogapendekin alfa inbak...
Mar 12, 2026 at 4:05 PM
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia...
Mar 12, 2026 at 4:00 PM
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025. “Adicet closed the year with solid momentum, driven by strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the...
Mar 12, 2026 at 2:04 PM
Virta Health’s Nutrition Therapy Extends Survival by 34% in Stage IV Pancreatic Cancer Patients, New Clinical Trial Shows
DENVER--(BUSINESS WIRE)--Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced pancreatic cancer is treated. Conducted in partnership with USC Norris Comprehensive Cancer Center, Mayo Clinic, HonorHealth Research Institute, and others, the study was peer-reviewed and published in Cancer, revealing that Virta’s medically supervised, individualized nutri...
Mar 12, 2026 at 12:00 PM
Foundation Medicine Launches Whole Genome Sequencing Germline Test for Research Use to Accelerate Biopharmaceutical Research and Therapy Development Beyond Oncology
BOSTON--(BUSINESS WIRE)--Foundation Medicine launches its Whole Genome Sequencing Germline test for research use to support translational research and drug discovery....
Mar 12, 2026 at 9:30 AM
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing
PARIS--(BUSINESS WIRE)--Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovatio...
Media & Journalist Tools
From headlines to storylines—Business Wire delivers the news you need, when you need it.